Literature DB >> 10623831

The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction.

J Schmitz1, H Dahmen, C Grimm, C Gendo, G Müller-Newen, P C Heinrich, F Schaper.   

Abstract

The function of the signal-transducing receptor subunit glycoprotein 130 (gp130) in the IL-6-receptor complex has previously been studied using carboxyl-terminal deletion mutants or a truncated molecule of approximately 60 membrane-proximal amino acids (containing box 1 and box 2) linked to the individual gp130 tyrosine motifs. However, the redundancy of the tyrosine motifs within the cytoplasmic part of gp130 has been neglected. Here we describe the analysis of the function of the individual cytoplasmic tyrosine residues of gp130 in the context of the full-length receptor protein in IL-6 signaling as measured by STAT activation, acute phase protein induction, and stimulation of proliferation. Add-back receptor mutants containing only one cytoplasmic tyrosine have been generated and tested for their efficiency in IL-6 signal transduction. Our studies revealed that tyrosine motifs which have been described to recruit STAT proteins are not equivalent with respect to their potential to activate STAT factors and acute phase protein gene promoters: the two distal tyrosines, Tyr905 and Tyr915, of gp130 were more potent than Tyr767 and Tyr814. Surprisingly, Tyr905 and Tyr915 mediate acute phase protein gene promoter activation stronger than the wild-type receptor containing all six cytoplasmic tyrosine residues. In contrast, Ba/F3 cells stably transfected with add-back receptors containing Tyr767 or Tyr905 were more sensitive to IL-6-induced proliferation than cells expressing the other add-back receptor mutants. Thus, the tyrosine residues in the cytoplasmic part of gp130 were found to contribute differentially to IL-6 signal transduction in the full- length gp130 protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623831     DOI: 10.4049/jimmunol.164.2.848

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  A single amino acid substitution (Trp(666)-->Ala) in the interbox1/2 region of the interleukin-6 signal transducer gp130 abrogates binding of JAK1, and dominantly impairs signal transduction.

Authors:  C Haan; H M Hermanns; P C Heinrich; I Behrmann
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation.

Authors:  Claude Haan; Peter C Heinrich; Iris Behrmann
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

Review 3.  Leukemia inhibitory factor (LIF).

Authors:  Nicos A Nicola; Jeffrey J Babon
Journal:  Cytokine Growth Factor Rev       Date:  2015-07-04       Impact factor: 7.638

4.  Kinetics of cytokine receptor trafficking determine signaling and functional selectivity.

Authors:  Jonathan Martinez-Fabregas; Stephan Wilmes; Luopin Wang; Majid Kazemian; Suman Mitra; Ignacio Moraga; Maximillian Hafer; Elizabeth Pohler; Juliane Lokau; Christoph Garbers; Adeline Cozzani; Paul K Fyfe; Jacob Piehler
Journal:  Elife       Date:  2019-11-27       Impact factor: 8.140

5.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

6.  Temporal expression of mRNAs for neuropoietic cytokines, interleukin-11 (IL-11), oncostatin M (OSM), cardiotrophin-1 (CT-1) and their receptors (IL-11Ralpha and OSMRbeta) in peripheral nerve injury.

Authors:  Y Ito; M Yamamoto; M Li; N Mitsuma; F Tanaka; M Doyu; A Suzumura; T Mitsuma; G Sobue
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

7.  Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.

Authors:  Emma C Walker; Rachelle W Johnson; Yifang Hu; Holly J Brennan; Ingrid J Poulton; Jian-Guo Zhang; Brendan J Jenkins; Gordon K Smyth; Nicos A Nicola; Natalie A Sims
Journal:  J Biol Chem       Date:  2016-08-18       Impact factor: 5.157

8.  A completely foreign receptor can mediate an interferon-gamma-like response.

Authors:  B Strobl; V Arulampalam; H Is'harc; S J Newman; J F Schlaak; D Watling; A P Costa-Pereira; F Schaper; I Behrmann; K C Sheehan; R D Schreiber; F Horn; P C Heinrich; I M Kerr
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

Review 9.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 10.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.